Search PubMed⌕ Search

Biomedical subjects

B M Cox

Publications and source records attributed to B M Cox.

At least 37 records · Page 2Linked to original sources

Mu opioid receptor mRNA in nucleus accumbens is elevated following dopamine receptor activation.

We have previously demonstrated that continuous cocaine treatment for three days induces a marked but transient increase in mu opioid receptor (MOR) mRNA in nucleus accumbens (n. acc.); SCH 23390 and eticlopride, selective antagonists of D1- and D2-like dopamine (DA) receptors, respectively, blocked this cocaine-induced upregulation of MOR mRNA in n. acc. suggesting involvement of both subfamilies of DA receptors in the effect of cocaine (1,2). In the present study the ability of the selective DA D3 receptor antagonist, nafadotride (3,4), to prevent the cocaine-induced upregulation of MOR mRNA in n. acc. has been examined. Also, regulation of MOR mRNA following chronic administration of the DA agonists, SKF 38393, R(+)-6-Bromo-APB hydrobromide, or bromocriptine, has been studied. Male Sprague-Dawley rats were treated for 3 days with saline, cocaine, the DA receptor agonists or antagonist delivered by osmotic minipump. Expression of MOR mRNA in n. acc. was estimated by quantitative competitive polymerase chain reaction (PCR) assays following reverse transcription. Nafadotride (1.0 mg/kg/day) prevented the cocaine-induced upregulation of MOR mRNA in n. acc. When administered alone, nafadotride did not change the expression of MOR mRNA. The levels of MOR mRNA were elevated in n. acc. after 3 days treatment with each of the DA agonists, SKF 38393 (4.0 mg/kg/day), R(+)-6-Bromo-APB hydrobromide (4.0 mg/kg/day), or bromocriptine (5.0 mg/kg/day). Thus, DA agonists mimick the effect of cocaine on the expression of MOR mRNA in n. acc. These data confirm the involvement of dopaminergic mechanisms in the mediation of cocaine effects, indicate the comparability of actions of indirect and direct DA agonists, and point to the usefulness of cocaine as a tool to expose interaction between dopaminergic and opioid systems. The results suggest that activation of more than one type of DA receptor is required for the increased expression of MOR mRNA.

Animals↗

Chronic intracerebroventricular cocaine differentially affects prodynorphin gene expression in rat hypothalamus and caudate-putamen.

We investigated the effects of sustained administration of cocaine on the regulation of prodynorphin gene expression in rat brain. Intracerebroventricular (i.c.v.) infusion of cocaine hydrochloride (30 micrograms/day) for 7 days, by means of osmotic minipumps, elicited a significant 35% decrease of prodynorphin mRNA levels in rat hypothalamus and increase (22%) in caudate-putamen. At the same time and in the same animals, no significant changes were detected in the hippocampus or in the nucleus accumbens. These results indicate that continuously infused cocaine is able to modulate expression of the prodynorphin gene in opposite directions or has no effect on prodynorphin expression, depending on the brain region analysed. Cocaine, as well as opiates, might activate specific neuronal pathways, shared by different classes of drugs of abuse, involving, at least in part, the endogenous opioid system.

Animals↗

Effect of chronic cocaine treatment on mu- and delta-opioid receptor mRNA levels in dopaminergically innervated brain regions.

The regulation of mu- (MOR) and delta-opioid receptor (DOR) after chronic cocaine administration has been studied. Male Sprague-Dawley rats were treated for 3 days with saline and cocaine (50 mg/kg/day) delivered by osmotic minipump. Expression of MOR and DOR mRNA in olfactory bulb, nucleus accumbens, and caudate-putamen (caudal and rostral parts) was estimated using quantitative competitive PCR assays after reverse transcription. No changes in the levels of mRNA for DOR were detected after exposure to cocaine in the brain regions examined. A significant increase in the level of MOR mRNA was detected in nucleus accumbens after 3 days of cocaine treatment. In caudate-putamen and olfactory bulb, no change in MOR mRNA was observed after cocaine administration. Both SCH 23390 and eticlopride, selective antagonists of D1- and D2-dopamine receptors, respectively, blocked this cocaine-induced up-regulation of MOR mRNA in nucleus accumbens. We suggest that endogenous opioid systems in nucleus accumbens, the brain region specifically associated with the reinforcing properties of addictive drugs, are regulated by dopaminergic mechanisms and influenced by cocaine treatment.

Animals↗

Differential desensitization of mu- and delta- opioid receptors in selected neural pathways following chronic morphine treatment.

1. Morphine produces a plethora of pharmacological effects and its chronic administration induces several side-effects. The cellular mechanisms by which opiates induce these side-effects are not fully understood. Several studies suggest that regulation of adenylyl cyclase activity by opioids and other transmitters plays an important role in the control of neural function. 2. The aim of this study was to evaluate desensitization of mu- and delta- opioid receptors, defined as a reduced ability of opioid agonists to inhibit adenylyl cyclase activity, in four different brain structures known to be involved in opiate drug actions: caudate putamen, nucleus accumbens, thalamus and periaqueductal gray (PAG). Opiate regulation of adenylyl cyclase in these regions has been studied in control and morphine-dependent rats. 3. The chronic morphine treatment used in the present study (subcutaneous administration of 15.4 mg morphine/rat/day for 6 days via osmotic pump) induced significant physical dependence as indicated by naloxone-precipitated withdrawal symptoms. 4. Basal adenylyl cyclase in the four brain regions was not modified by this chronic morphine treatment. In the PAG and the thalamus, a desensitization of mu- and delta-opioid receptors was observed, characterized by a reduced ability of Tyr-D-Ala-Gly-(NMe)Phe-Gly-ol (DAMGO; mu), Tyr-D-Pen-Gly-Phe-D-Pen (DPDPE; delta) and [D-Ala2]-deltorphin-II (DT-II; delta) to inhibit adenylyl cyclase, activity following chronic morphine treatment. 5. The opioid receptor desensitization in PAG and thalamus appeared to be heterologous since the metabotropic glutamate receptor agonists, L-AP4 and glutamate, and the 5-hydroxytryptamine (5-HT)1A receptor agonist, R(+)-8-hydroxy-2-(di-n-propylamino)tetralin hydrobromide (8-OH-DPAT), also showed reduced inhibition of adenylyl cyclase activity following chronic morphine treatment. 6. In the nucleus accumbens and the caudate putamen, desensitization of delta-opioid receptor-mediated inhibition without modification of mu-opioid receptor-mediated inhibition was observed. An indirect mechanism probably involving dopaminergic systems is proposed to explain the desensitization of delta-mediated responses and the lack of mu-opioid receptor desensitization after chronic morphine treatment in caudate putamen and nucleus accumbens. 7. These results suggest that adaptive responses occurring during chronic morphine administration are not identical in all opiate-sensitive neural populations.

8-Hydroxy-2-(di-n-propylamino)tetralin↗

Differential regulation of D1 dopamine receptor- and of A2a adenosine receptor-stimulated adenylyl cyclase by mu-, delta 1-, and delta 2-opioid agonists in rat caudate putamen.

Inhibition and stimulation of adenylyl cyclase by opioid and D1 dopamine or A2a adenosine agonists, respectively, were characterized in the caudate putamen of rats. D1 dopamine receptors have been reported to be localized preferentially on striatonigral neurons and A2a adenosine receptors on striatopallidal neurons. The aim of the present study was to evaluate the effects of mu-[Tyr-D-Ala-Gly-(N-Me)Phe-Gly-ol (DAMGO)], delta 1-[Tyr-D-Pen-Gly-Phe-D-Pen (DPDPE)], and delta 2- ([D-Ala2]deltorphin-II [DT-II]) opioid agonists on the D1 dopamine receptor- and A2a adenosine receptor-stimulated adenylyl cyclase in membranes from rat caudate putamen. The results show that DAMGO, DPDPE, and DT-II inhibit forskolin-stimulated adenylyl cyclase [selectively antagonized by D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2 (CTOP; mu antagonist), 7-benzylidenenaltrexone (BNTX; delta 1 antagonist), and naltriben (NTB; delta 2 antagonist), respectively], but only mu- and delta 2-opioid agonists inhibit D1 dopamine-stimulated adenylyl cyclase (antagonized by CTOP and NTB, respectively). Furthermore, DT-II and DPDPE inhibit A2a adenosine-stimulated adenylyl cyclase (antagonized by NTB and BNTX, respectively), whereas DAMGO did not inhibit A2a adenosine-stimulated adenylyl cyclase activity. These results suggest that mu-, delta 1-, and delta 2-opioid receptors display differential localization and provide neurochemical evidence suggesting the differential location of the delta 1 and delta 2 subtypes. mu-Opioid receptors may be preferentially expressed by striatonigral neurons, delta 1-by striatopallidal neurons, and delta 2-by these two striatal efferent neuron populations.

Adenylyl Cyclases↗

Opioid-induced increase in [Ca2+]i in ND8-47 neuroblastoma x dorsal root ganglion hybrid cells is mediated through G protein-coupled delta-opioid receptors and desensitized by chronic exposure to opioid.

delta-Receptor agonists induce a concentration-dependent increase in intracellular calcium concentration ([Ca2+]i) in ND8-47 cells by activating dihydropyridine-sensitive Ca2+ channels. The role of G proteins in transducing the opioid effect has been studied. Pretreatment of cells with pertussis toxin (100 ng/ml, 24 h) almost completely blocked [D-Ser2,Leu5]enkephalin-Thr (DSLET)-induced increase in [Ca2+]i. Cholera toxin (10 nM, 24 h) had no effect on DSLET-induced response. Pretreatment of the cells with 1 microM DSLET for 1 h resulted in a 30% inhibition of DSLET-induced increase in [Ca2+]i and a 78% inhibition after exposure for 24 h. After 1 h of exposure to DSLET, there was a decrease in agonist affinity with no significant changes in receptor density. Cells exposed to 1 microM DSLET for 24 h demonstrate a nearly 90% decrease in [3H]diprenorphine binding, with a decrease in affinity for agonist at the remaining binding sites. G protein subunits alpha i2, alpha i3, alpha s, and alpha q were detected in ND8-47 cell membranes by western blot; alpha o and alpha i1 were not present. Chronic DSLET treatment had no significant effect on the quantity of each of the alpha-subunits. These results suggest that the DSLET-induced increase in [Ca2+]i mediated through pertussis toxin-sensitive G proteins (probably Gi2 or Gi3) and the attenuation of this response in chronically treated cells is associated with a relatively rapid reduction in receptor affinity to DSLET and a slow reduction in receptor density.

Calcium↗

Antisense oligodeoxynucleotide to the Gi2 protein alpha subunit sequence inhibits an opioid-induced increase in the intracellular free calcium concentration in ND8-47 neuroblastoma x dorsal root ganglion hybrid cells.

In ND8-47 cells, a neuroblastoma x dorsal root ganglion hybrid cell line, activation of delta-opioid receptors induced an increase in the intracellular free calcium concentration ([Ca2+]i) through dihydropyridine-sensitive calcium channels. This effect was mediated by pertussis toxin-sensitive G proteins. The G protein alpha subunits alpha i2, alpha i3, alpha q, and alpha s were detected using Western blots, whereas alpha o and alpha i1 were not found in ND8-47 cell membranes. To identify the specific G protein alpha subunit(s) responsible for the increase in [Ca2+]i, we treated ND8-47 cells with antisense oligodeoxynucleotides (AS) complementary to the mRNA for each G protein alpha subunit (alpha i2, alpha i3, or alpha s), at a concentration of 10 microM, for up to 6 days and examined their effects on opioid-induced increases in [Ca2+]i and on the levels of G protein alpha subunits. [Ca2+]i was measured in adherent cells using the fluorescent dye fura-2. Treatment of cells with alpha i2-AS (10 microM, for 6 days) resulted in a 73% inhibition of the [D-Ser2,Leu5]-enkephalin-Thr-induced increase in [Ca2+]i. In contrast, pretreatment of cells with alpha i3-AS (10 microM, for 6 days) or alpha s-AS (10 microM, for 6 days) had no effect on the [D-Ser2,Leu5]-enkephalin-Thr-induced responses. Western blots indicated that the levels of alpha i2 were decreased when cells were exposed to alpha i2-AS (10 microM) for 6 days, whereas the levels of alpha i3, alpha s, and alpha q were not affected by this treatment. Treatment of the cells with alpha i3-AS or alpha s-AS for 6 days significantly reduced alpha i3 or alpha s levels, respectively. These results indicate that the opioid-induced increase in [Ca2+]i in ND8-47 cells is mediated by G alpha i2.

Analgesics↗

Evidence for delta opioid receptor subtypes regulating adenylyl cyclase activity in rat brain.

Opioid agonists selective for mu- or delta opioid receptors inhibit adenylyl cyclase in membranes from rat caudate-putamen and nucleus accumbens. The presence of subtypes of delta opioid receptors has been suggested. In both brain regions we have found that the inhibition of adenylyl cyclase by DPDPE was more readily antagonized by 7-benzylidenenaltrexone (BNTX), than by naltriben. In contrast, the inhibitory effects of deltorphin-II and DSLET were more readily antagonized by naltriben, than by BNTX. Neither naltriben nor BNTX significantly antagonized the effect of a mu selective agonist. These results suggest that inhibition of adenylyl cyclase in caudate-putamen and nucleus accumbens is regulated by two forms of delta-opioid receptor with ligand selectivities similar to those two forms proposed to mediate analgesic effect.

Adenylyl Cyclase Inhibitors↗

Opioids acting through delta receptors elicit a transient increase in the intracellular free calcium concentration in dorsal root ganglion-neuroblastoma hybrid ND8-47 cells.

The neuronal cell line ND8-47 (neuroblastoma x dorsal root ganglion neuron hybrid) expressed opioid delta-type receptors. We report opioid-induced changes in cytosolic intracellular free calcium ([Ca++]i) in differentiated ND8-47 cells. Delta-opioid receptor agonists induced a transient (< 2 min) increase in [Ca++]i in a concentration-dependent fashion with the potency order: [D-Ser2,Leu5]enkephalin-Thr (DSLET) > or = deltorphin II > [D-Pen2,5] enkephalin. Their effects were blocked by naloxone (IC50 = 20 nM) and naltrindole (IC50 = 2.5 nM). Selective mu and kappa receptor agonists had no effect on [Ca++]i. The subtype specific delta receptor antagonists, 7-benzylidene naltrexone (delta-1) and naltriben (delta-2), were used to characterize further the subtype of delta receptors mediated by this response. Naltriben was more potent than 7-benzylidene naltrexone in antagonizing the DSLET-induced increase in [Ca++]i. The increase in [Ca++]i induced by DSLET was blocked by nifedipine (1 microM) or verapamil (1 microM), and was not observed in the absence of external calcium. Changes in [Ca++]i also were measured in single ND8-47 cells. The percentage of cells responding to DSLET (1 microM), deltorphin-II (1 microM) and [D-Pen2,5]enkephalin (1 microM) were 86, 84 and 37%, respectively. The results suggest that an increase in [Ca++]i induced by opioids is mediated through opioid delta receptors which can activate dihydropyridine-sensitive Ca++ channels.

Analgesics↗

Chronic repeated cocaine administration alters basal and opioid-regulated adenylyl cyclase activity.

Repeated daily cocaine injections have been shown to alter mu-opioid receptor densities in the caudate putamen and nucleus accumbens of rat brain (Unterwald et al., 1991, 1992). Adenylyl cyclase activity was measured in rat rostral caudate putamen and nucleus accumbens following repeated cocaine administration to determine the functional consequences of cocaine-induced opioid receptor changes. Male Fischer rats were injected daily for 14 days with saline or cocaine HCl (30 or 45 mg/kg/day, i.p.) in three equal doses at 1-hr intervals. Basal adenylyl cyclase activity and the effects of the selective mu- and delta-opioid agonists [D-Ala2,N-Me-Phe4,Gly-ol5]enkephalin (DAMGO) and [D-penicillamine2,D-Penicillamine5]enkephalin (DPDPE), respectively, on adenylyl cyclase activity were examined 30 min after the last injection using a cAMP radioligand binding assay in crude membrane preparations. Basal adenylyl cyclase activity was 49% and 34% lower in the caudate putamen of animals treated with 30 and 45 mg/kg/day of cocaine, respectively, as compared to those receiving saline injections. Basal adenylyl cyclase activity was unchanged in the nucleus accumbens following cocaine treatment. DAMGO and DPDPE each maximally inhibited approximately 25% and 30%, respectively, of basal adenylyl cyclase in the caudate putamen and nucleus accumbens of saline-injected animals. Administration of cocaine attenuated the ability of DPDPE to inhibit adenylyl cyclase in both brain regions, but had no effect on the efficacy or potency of DAMGO for inhibiting adenylyl cyclase activity. These results suggest that chronic, repeated cocaine administration results in a selective impairment of delta-opioid receptor-mediated effector function in the caudate putamen and nucleus accumbens.

Adenylyl Cyclases↗

The cocaine analog WIN 35,428 binds to two sites in fresh rat caudate-putamen: significance of assay procedures.

Binding of the potent cocaine analog [3H]WIN 35,428 (2 beta-carbomethoxy-3 beta-(4-fluoro-phenyl)-tropane) was examined in membrane homogenates prepared from fresh rat caudate-putamen. The number of rinses of the membranes following incubation with the ligand was varied. After one wash, only a single binding site was evident. With an increasing number of washes, however, two binding sites were observed. Additional rinses, up to a total of four, led to a decrease in the number of low affinity binding sites, with no change in the number of high affinity sites. These results suggest that the methodology used in these binding assays may be important for interpretation of the results.

Animals↗

Differential regulation of adenylyl cyclase activity by mu and delta opioids in rat caudate putamen and nucleus accumbens.

The regulation of adenylyl cyclase by opioid receptor types was characterized in the rat nucleus accumbens, a brain region that is involved in the reinforcing effects of drugs of abuse, and in the caudate putamen, a region not implicated in drug reinforcement. Both mu and delta opioid ligands inhibited adenylyl cyclase activity in the nucleus accumbens and in the caudate putamen of rat, whereas the kappa agonist, U69,593 (5 alpha, 7 alpha, 8 alpha)-(+)-N-methyl-N-[7-(pyrrolidinyl)-1-oxaspiro [4,5]dec-8-yl]-benzeneacetamide, was ineffective. The mu agonists, DAMGO and Tyr-D-Arg-Phe-Sar, were more potent inhibitors of the enzyme in caudate putamen than in nucleus accumbens. The delta-selective agonists, DSLET and [D-Ala2]-deltorphin II more potently inhibited adenylyl cyclase in nucleus accumbens than in caudate putamen. Inhibition of the enzyme by DAMGO and Tyr-D-Arg-Phe-Sar was antagonized by the mu-selective competitive antagonist, CTOP D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2, and the noncompetitive mu antagonists, beta-funaltrexamine and naloxonazine. Inhibition of adenylyl cyclase activity by the delta-selective ligands, DPDPE, DSLET and [D-Ala2]-deltorphin II was unaffected by these antagonists. Conversely, the delta-selective antagonists, ICI 174,864 N-allyl2-Tyr-(alpha-aminisobutyric acid)2-Phe-Leu-OH and naltrindole, blocked the effects of the delta but not the mu opioid ligands. Adenylyl cyclase activity in nucleus accumbens and in caudate putamen is subject to regulation by both mu and delta opioid receptors.

Adenylyl Cyclases↗

Inhibition of norepinephrine release from rat cortex slices by opioids: differences among agonists in sensitivities to antagonists suggest receptor heterogeneity.

Receptors mediating opiate-induced inhibition of potassium-stimulated release of [3H]norepinephrine (NE) from slices of rat cortex incubated in vitro have been characterized by comparison of the pA2 values of the competitive antagonists, naloxone, D-Pen-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2 (CTOP), nor-binaltorphimine, naltrindole and bremazocine against the agonists, Tyr-D-Ala-MePhe-Gly-ol (DAMGO), Tyr-D-Arg-Phe-Sar (TAPS), [D-Ser2, Leu5]enkephalyl-Thr (DSLET), beta-endorphin [beta-END(1-31)] and ethylketocyclazocine (EKC). There were significant differences among agonists in their sensitivities to each antagonist. The delta receptor selective agonist, DPDPE, and the kappa 1-agonist, U69593, did not inhibit NE release, indicating that delta and kappa 1 receptors are not involved. DAMGO, TAPS and DSLET generally behaved as mu agonists, although TAPS and DSLET were less sensitive to antagonism by CTOP than by DAMGO. TAPS and DSLET showed similar sensitivities to all antagonists, suggesting that they acted through similar receptors, possibly of the mu 1 type. beta-END(1-31) and EKC differed from DAMGO and from each other in their sensitivities to most antagonists. Shifts in agonist concentration-response curves induced by prior treatment of the rats with the noncompetitive antagonists, beta-funaltrexamine and naloxonazine, also suggested that EKC and beta-END(1-31) acted through mechanisms differing from those used by DAMGO, TAPS and DSLET. It is possible that EKC and beta-END(1-31) acted via kappa 2 and/or epsilon receptors. These results suggest that there is heterogeneity in the opioid receptors regulating NE release in rat cortex.

Amino Acid Sequence↗

Inhibition of dopamine uptake by cocaine and nicotine: tolerance to chronic treatments.

Chronic administration of cocaine (50 mg/kg/day for 7 days, s.c. via an osmotic minipump) produced tolerance to inhibition of [3H]dopamine uptake by cocaine in rat striatum but did not produce cross-tolerance to inhibition of [3H]dopamine uptake by nicotine. Chronic nicotinic treatment (6 mg/kg/day for 7 days, s.c. via an osmotic minipump), however, produced tolerance to the inhibition of [3H]dopamine uptake by nicotine and cross-tolerance to inhibition of uptake by cocaine in rat striatum. Nicotine did not inhibit uptake of [3H]dopamine in the nucleus accumbens of saline-treated animals. In this tissue, both cocaine and nicotine treatments produced tolerance to cocaine, as in striatum. Unlike the effects on [3H]dopamine uptake, chronic cocaine infusion did not have any effect on the ability of cocaine to inhibit [3H]serotonin uptake in either brain region.

Animals↗

Inhibition of [3H]dopamine and [3H]serotonin uptake by cocaine: comparison between chopped tissue slices and synaptosomes.

Cocaine inhibits both [3H]dopamine and [3H]serotonin uptake in rat striatum and nucleus accumbens. In a chopped tissue slice preparation, the inhibition curve for [3H]dopamine uptake is biphasic, suggesting two components of uptake, whereas the curve for [3H]serotonin uptake is steep and apparently monophasic. In synaptosomal preparations, both curves are monophasic. Monensin, a sodium ionophore, inhibits uptake but does not change the shape of the cocaine inhibition curve in synaptosomes, suggesting that the biphasic inhibition curves in slices are not likely due to differential sodium gradients across the slices. In tissue slices, only the component which is more sensitive to inhibition by cocaine and related drugs is inhibitable by nicotine. This suggests that the two components of dopamine uptake in tissue slices may be differentially regulated.

Animals↗

Serotonin-stimulated release of [3H]dopamine via reversal of the dopamine transporter in rat striatum and nucleus accumbens: a comparison with release elicited by potassium, N-methyl-D-aspartic acid, glutamic acid and D-amphetamine.

Release of preloaded radiolabeled dopamine ([3H]DA) elicited by several agents from terminal fields of mesolimbic and nigrostriatal projections in rats was compared. Several similarities between the two areas were observed. For example, potassium, which stimulates release both directly, through altering the potential across the membrane of the dopaminergic neuron, as well as indirectly, presumably by releasing endogenous excitatory neurotransmitters, exhibited some similarities to release stimulated by L-glutamate and N-methyl-D-aspartic acid. These included sensitivity to tetrodotoxin (TTX), Mg++ and Ca++. In contrast, release of [3H]DA stimulated by serotonin (5-HT), like that stimulated by D-amphetamine, depended upon a functional dopamine transport system and was less sensitive to TTX, Mg++ and Ca++. 5-HT-stimulated [3H]DA release in striatum (STR) and nucleus accumbens (NACC) was not modified by antagonists at 5-HT2 or 5-HT3 receptors. Differences were observed in release of [3H]DA from STR and NACC. Elevated potassium (20 mM) released about twice as much [3H]DA from NACC as it did from STR. 5-HT was also able to release more [3H]DA from NACC than from STR. Conversely, D-amphetamine released more [3H]DA from STR than from NACC. TTX increased release stimulated by potassium in STR, but decreased release stimulated by potassium in NACC. These observations suggest that receptor- and non-receptor-mediated mechanisms may contribute to regulation of [3H]DA release in mesolimbic and nigrostriatal areas of the brain. It is possible that endogenous 5-HT in STR or NACC acts as a local regulator of DA release acting via a transport-dependent mechanism.(ABSTRACT TRUNCATED AT 250 WORDS)

Amphetamine↗

Comparison of dopamine uptake and release in vitro in sheep and rat striatum.

Cocaine inhibits tritium-labeled dopamine ([3H]DA) uptake in rat (IC50 approximately 400 nM) and sheep (IC50 approximately 1 microM) striatum. GBR 12909, a selective DA uptake inhibitor, potently inhibits [3H]DA uptake in rat (IC50 less than 10 nM), but is less effective (only 60% of the uptake is inhibited at a concentration of 10 microM) and less potent (IC50 approximately 300 nM) in sheep. [3H]DA release from slices of rat or sheep striatum is stimulated by potassium (15-50 mM). In the presence of nomifensine (10 microM), cocaine (10 microM) had no effect on potassium-stimulated [3H]DA release in either species. [3H]DA release is increased by N-methyl-D-aspartate (NMDA) (10-1000 microM) in rat striatum but NMDA did not stimulate [3H]DA release in sheep striatum. These findings suggest that NMDA receptors either are absent from or do not regulate release of preloaded [3H]DA in sheep striatum.

Animals↗

Nicotine indirectly inhibits [3H]dopamine uptake at concentrations that do not directly promote [3H]dopamine release in rat striatum.

The effects of both (-)- and (+)-nicotine isomers were examined on in vitro uptake and release of [3H]dopamine in rat striatum. Both isomers inhibited uptake of [3H]dopamine in chopped tissue at concentrations well below those necessary for promoting release of preloaded [3H]dopamine. (-)-Nicotine was more potent than (+)-nicotine both at inhibiting uptake and at promoting release. Unlike other dopamine uptake inhibitors, however, nicotine inhibited only 50% of the total uptake. In the presence of 1 nM nicotine, the residual [3H]dopamine uptake was less sensitive to inhibition by cocaine than uptake in the absence of nicotine. Nicotine did not compete against the binding of [3H]GBR 12935, a selective dopamine uptake inhibitor. The nicotinic receptor agonists carbachol and 1,1-dimethyl-4-phenylpiperazinium iodide also inhibited uptake, whereas the nicotinic antagonists chlorisondamine and mecamylamine blocked nicotine's effect. Thus, the effect of nicotine on dopamine uptake appears to be mediated by a receptor similar to the nicotinic acetylcholine receptor. These receptors do not seem to be on the terminals that are accumulating dopamine, however, since tetrodotoxin prevented the effect of nicotine on [3H]dopamine uptake and nicotine had no effect on uptake in a synaptosomal preparation.

Animals↗